Navigating Through the Healthcare SystemVideo Categories: Pharmacy
Supported through funding from Incyte
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Dixie-Lee Esseltine, MD and George Mulligan, PhD explain ixazomib’s mechanism of action and how the drug may fit into the treatment regimen for patients upon approval and beyond.